These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16277272)

  • 21. Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
    Sato Y; Honda Y; Iwamoto J; Amano N
    J Musculoskelet Neuronal Interact; 2013 Sep; 13(3):346-52. PubMed ID: 23989256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Application of anti-resorptive drugs for the treatment of osteoporosis].
    Takada J
    Nihon Rinsho; 2006 Feb; 64(2):385-91. PubMed ID: 16454196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
    Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD; Faber H; Farahmand P; Dorst A
    Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
    Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
    J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
    Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis].
    Ohbayashi H
    Nihon Rinsho; 2009 Jan; 67(1):206-12. PubMed ID: 19177774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
    Boonen S; Laan RF; Barton IP; Watts NB
    Osteoporos Int; 2005 Oct; 16(10):1291-8. PubMed ID: 15986101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
    Sato S
    Clin Calcium; 2007 Apr; 17(4):600-5. PubMed ID: 17404491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Osteoporosis treatment: choices and options].
    Reginster JY
    Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
    [No Abstract]   [Full Text] [Related]  

  • 34. Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
    Iwasaki T; Takei K; Nakamura S; Hosoda N; Yokota Y; Ishii M
    Pediatr Int; 2008 Jun; 50(3):269-75. PubMed ID: 18533934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoporosis in men.
    Lems WF; Geusens PP
    N Engl J Med; 2008 Aug; 359(8):868; author reply 869. PubMed ID: 18724402
    [No Abstract]   [Full Text] [Related]  

  • 36. Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
    Ye Y; Hu SJ
    Bone; 2009 Sep; 45(3):609-10; author reply 611. PubMed ID: 19465167
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
    [No Abstract]   [Full Text] [Related]  

  • 39. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
    Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC
    Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.
    Li CY; Price C; Delisser K; Nasser P; Laudier D; Clement M; Jepsen KJ; Schaffler MB
    J Bone Miner Res; 2005 Jan; 20(1):117-24. PubMed ID: 15619677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.